Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Endocrine Research|January 26, 2005
The triple A syndrome is due to mutations in ALADIN, a novel member of the nuclear pore complexAngela Huebner, A M Kaindl, K P Knobeloch, et al.The Thoracic and Cardiovascular Surgeon|March 13, 2001
Does the time of resternotomy for bleeding have any influence on the incidence of sternal infections, septic courses or further complications?U Boeken, J Eisner, P Feindt, et al.Pancreas|April 1, 1996
Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreasM Löhr, B Trautmann, M Göttler, et al.Virchows Archiv : an International Journal of Pathology|July 27, 2001
Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-rasM Löhr, P Müller, I Zauner, et al.Hepato-Gastroenterology|January 8, 2000
Serum levels of extracellular matrix in acute pancreatitisM Löhr, F Hummel, P Martus, et al.Gene Therapy|May 18, 1999
Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450M Löhr, P Müller, P Karle, et al.Advances in Experimental Medicine and Biology|February 23, 1999
Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapyP Karle, P Müller, R Renz, et al.European Journal of Clinical Investigation|March 27, 2001
Low frequency of p53 and ras mutations in bile of patients with hepato-biliary disease: a prospective study in more than 100 patientsP Müller, C Ostwald, K Püschel, et al.Annals of the New York Academy of Sciences|July 23, 1999
Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumorsP Müller, R Jesnowski, P Karle, et al.Gastrointestinal Endoscopy|May 26, 2001
p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitisM Löhr, P Müller, J Mora, et al.Pageof 9